4/A: Myriad Genetics CFO Corrects Stock Grant Reporting Error

Scott J. Leffler, CFO of Myriad Genetics, files an amendment to correct the number of restricted stock units granted on March 14, 2024.

Summary

• Scott J. Leffler, the Chief Financial Officer of Myriad Genetics, filed an amended Form 4 with the SEC.
• The amendment corrects a clerical error in the original filing from March 18, 2024, regarding the number of restricted stock units (RSUs) granted to Leffler on March 14, 2024.
• The original filing underreported the grant by 810 RSUs.
• The corrected filing shows that Leffler was granted 46,905 time-based restricted stock units on March 14, 2024, at a price of $0.
• These RSUs vest in three equal annual installments starting on the first anniversary of the grant date, according to the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• Following the reported transaction, Leffler beneficially owns 164,675 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The document corrects a minor error in a previous filing. While the error itself is slightly negative, the correction is a positive sign of transparency and diligence. Overall, the impact is neutral to slightly positive.

Negatives

• A clerical error led to an underreporting of restricted stock units granted to the CFO in the initial SEC filing.

Risks

• Clerical errors in SEC filings, while often minor, can raise concerns about internal controls and accuracy of financial reporting.

Future Outlook

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives. The vesting schedule aligns the executive's interests with the long-term performance of the company.

Comparison to Industry Standards

• Equity grants to CFOs in similar-sized biotech companies typically include a mix of stock options and restricted stock units.
• Vesting schedules of three to four years are standard in the industry to incentivize long-term commitment.
• Companies like Exact Sciences and Invitae also utilize similar equity compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the correction as a sign of diligence and transparency from management.
• Employees may see the equity grants as a positive sign of the company's commitment to its employees.

Key Dates